NCT00946725

CompletedPhase 1

To Demonstrate the Relative Bioavailability of Atenolol Tabl...

Sandoz Source

Compare

Other study identifiers

Sponsor study identifier

11627

Study Type

interventional

Actual enrollment (reported)

28

Locations

0 countries

Sites

N/A

Timeline

Study Start

November 2000

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

November 2000

Actual (reported)

Study Completion

November 2000

Actual (reported)

Brief Summary

To demonstrate the relative bioavailability of atenolol tablets, 100 mg.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 28 participants
Study completion date: November 2000
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
November 2000
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
November 2000
Actual (reported)
Study Completion
November 2000
Actual (reported)
First Submitted
July 24, 2009
Actual (reported)
First Posted
July 27, 2009
Actual (reported)

Last Updated: March 28, 2017
Status Verified: July 2009
Last Update Submitted: March 27, 2017

Conditions

Angina Hypertension

Keywords

Angina (Chest Pain)Hypertension

Outcome Measures

Primary Outcomes (1)

Bioequivalence based on AUC and Cmax
20 days

Study Arms (2)

1

EXPERIMENTAL

Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)

Drug: Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)

2

ACTIVE COMPARATOR

Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)

Drug: Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)

Interventions

Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)Drug

2

Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)Drug

1

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 50 Years

Sexmale

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

You may not qualify if:

Sponsors & Collaborators

Sandoz
Industrylead

MeSH Terms

Conditions

Angina PectorisHypertensionChest Pain

Interventions

Atenolol

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Phenoxypropanolamines

Study Officials

Ronald Goldwater, M.D.
PharmaKinetics Laboratories Inc.
PRINCIPAL INVESTIGATOR

Enrollment

28 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: CROSSOVER
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

July 24, 2009

First Posted

July 27, 2009

Study Start

November 2000

Date type not reported

This date has not been verified as actual or estimated.

NCT00946621

To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions

Phase 1Completed

NCT00865176

Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fasting Conditions

Phase 1Completed

NCT00865618

Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fed Conditions

Phase 1Completed

SYF39f392fdfdff4baeba207b2bf87578e6

A randomized, single dose, cross-over bioavailability study comparing the drug-drug interaction between telmisartan tablets, indapamide tablets, and amlodipine tablets when co-administered versus the administration of each product alone in three arms to healthy volunteers under fasting conditions.

Phase 1Unknown

NCT00223717

Treatment of Supine Hypertension in Autonomic Failure

Phase 1Completed

NCT00158093

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

Phase 1Completed

Positive test results for HIV or hepatitis B or C.

Treatment for drug or alcohol dependence.

Contact the study team to confirm eligibility.

Propanolamines

Amino Alcohols

Alcohols

Organic Chemicals

Propanols

Amines

Primary Completion

November 2000

Actual (reported)

Study Completion

November 2000

Actual (reported)

Last Updated

March 28, 2017

Record last verified: 2009-07

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00946725
Data provider: ClinicalTrials.gov
Source updated: 2017-03-28
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:28:37 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

1

2

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record